Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
220 hedge funds and large institutions have $4.68B invested in Blueprint Medicines in 2019 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 93 increasing their positions, 47 reducing their positions, and 34 closing their positions.
98% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 47
59% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 34
59% more call options, than puts
Call options by funds: $63.8M | Put options by funds: $40.2M
20% more capital invested
Capital invested by funds: $3.89B → $4.68B (+$789M)
8% more funds holding
Funds holding: 203 → 220 (+17)
8.63% less ownership
Funds ownership: 110.15% → 101.52% (-8.6%)
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$148M |
| 2 |
BlackRock
New York
|
+$58.6M |
| 3 |
HM
HealthCor Management
New York
|
+$31.6M |
| 4 |
CCM
Cadian Capital Management
New York
|
+$26.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$26.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$77.2M |
| 2 |
TGI
TRV GP II
Boston,
Massachusetts
|
-$70.4M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$21.1M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$21M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$16M |
BPMC Hedge Fund Activity: Q2 2019 in Review
220 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2019, worth a combined $4.68B — up 20% from $3.89B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new BPMC positions and 34 closed out — a net gain of 20 holders — while 93 added to existing stakes and 47 trimmed.
The largest buyer was Invesco, adding an estimated $148M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $77.2M sold.
- 220 institutional investors held Blueprint Medicines (BPMC) as of Q2 2019, up from 203 in Q1 2019.
- Funds reported $4.68B of Blueprint Medicines stock for Q2 2019, up 20% quarter-over-quarter.
- 54 funds opened new Blueprint Medicines positions in Q2 2019 and 34 closed out, a net change of +20 holders.
- The largest Blueprint Medicines buyer in Q2 2019 was Invesco, an estimated $148M added.
- The largest Blueprint Medicines seller in Q2 2019 was PFM Health Sciences, an estimated $77.2M sold.
Based on aggregated 13F filings for Q2 2019.